Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A user applied tretinoin to their scalp for hair loss and found brown particles in the cream. They are seeking information about these particles.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

Astaxanthin (ASX) is highlighted as a promising supplement for treating hair loss due to its antioxidant properties. It may help with inflammation and oxidative stress, which are linked to hair loss and aging.

Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hair follicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Individuals with oily scalps, dandruff, and diffuse thinning hair loss who have managed to either halt the loss or regrow their hair by using topical finasteride and minoxidil as well as microneedling and ketoconazole 2% shampoo.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Applying hair loss treatments like minoxidil and finasteride, with concerns about side effects and application timing. Some users experience side effects, while others manage without issues, and there's interest in future treatments like pyrilutamide.

Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.

A user noticed a color change in their hair loss solution containing minoxidil, finasteride, retinoic acid, and hydrocortisone after storing it for several months. They are concerned about the effectiveness of the solution due to potential oxidation.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.

The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.

The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.